NASDAQ: SRZN - Surrozen, Inc.

Altı ay boyunca karlılık: +41.17%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Surrozen, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

daha fazla ayrıntı
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2021-01-11
ISIN US86889P1093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.surrozen.com
Цена ао 11.89
Günlük fiyat değişimi: 0% (11.59)
Haftalık fiyat değişimi: -1.02% (11.71)
Aylık fiyat değişimi: +8.32% (10.7)
3 ayda fiyat değişimi: +15.9% (10)
Altı ayda fiyat değişimi: +41.17% (8.21)
Yıllık fiyat değişimi: -13.02% (13.325)
3 yılda fiyat değişimi: +219.28% (3.63)
5 yılda fiyat değişimi: 0% (11.59)
10 yılda fiyat değişimi: 0% (11.59)
Yılbaşından bu yana fiyat değişimi: -5.23% (12.23)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 1.35 9
P/BV 0.4458 10
P/E 0 0
EV/EBITDA 0.3831 10
Toplam: 6.13

Yeterlik

İsim Anlam Seviye
ROA, % -93.41 0
ROE, % -113.46 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0822 10
Toplam: 9.8

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 80.4 9
karlılık EPS, % 416.44 10
Toplam: 7.2
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Column Group LLC 627651 19.62
Euclidean Capital LLC 87696 2.74
Blackrock Inc. 58494 1.83
ArrowMark Colorado Holdings LLC 55123 1.72
Board Of Trustees Of The Leland Stanford Junior University 52131 1.63
Trustees Of Columbia University In The City Of New York 47930 1.5
Morgan Stanley 35211 1.1
Vanguard Group Inc 32511 1.02
Alyeska Investment Group, L.P. 20376 0.64
Geode Capital Management, LLC 11473 0.36

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
iShares Micro-Cap ETF 0.00519 17.09 1.54048



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Craig C. Parker M.B.A. CEO, President & Director 825.32k 1962 (63 yıl)
Mr. Charles Williams CFO, COO & Corporate Secretary 611.03k 1980 (45 yıllar)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board N/A
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1950 (75 yıllar)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor N/A
Dr. Li Yang Ph.D. Executive Vice President of Research 535.46k 1969 (56 yıllar)
Esther Jhun Controller N/A

Adres: United States, South San Francisco. CA, 171 Oyster Point Boulevard - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.surrozen.com